Professor Ed Lavelle

• Kearney CJ, Cullen SP, Tynan GA, Henry CM, Clancy D, Lavelle EC, Martin SJ, Necroptosis suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine production., Cell death and differentiation, 22, 2015, p1313-1327Journal Article, 2015, DOI
• Davitt, C.J.H., Lavelle, E.C., Delivery strategies to enhance oral vaccination against enteric infections, Advanced Drug Delivery Reviews, 2015Journal Article, 2015, DOI , TARA - Full Text
• Brown AF, Murphy AG, Lalor SJ, Leech JM, O'Keeffe KM, Mac Aogáin M, O'Halloran DP, Lacey KA, Tavakol M, Hearnden CH, Fitzgerald-Hughes D, Humphreys H, Fennell JP, van Wamel WJ, Foster TJ, Geoghegan JA, Lavelle EC, Rogers TR, McLoughlin RM, Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection., PLoS pathogens, 11, (11), 2015, pe1005226Journal Article, 2015, DOI , TARA - Full Text
• Finlay CM, Stefanska AM, Walsh KP, Kelly PJ, Boon L, Lavelle EC, Walsh PT, Mills KH., Helminth Products Protect against Autoimmunity via Innate Type 2 Cytokines IL-5 and IL-33, Which Promote Eosinophilia., Journal of Immunology, 196, (2), 2016, p703-714Journal Article, 2016, DOI
• Antigen Delivery Systems I: Nonliving Microparticles, Liposomes, and Immune-Stimulating Complexes (ISCOMs) in, Mucosal Immunology, 2015, pp1211-1231 , [McEntee, C., Lavelle, E.C., O'Hagan, D.T.]Book Chapter, 2015, DOI
• Arancibia, S., Espinoza, C., Salazar, F., Del Campo, M., Tampe, R., Zhong, T.-Y., De Ioannes, P., Moltedo, B., Ferreira, J., Lavelle, E.C., Manubens, A., De Ioannes, A.E., Becker, M.I., A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata promotes potent anti-tumor activity in melanoma, PLoS ONE, 9, (1), 2014, pe94703-Journal Article, 2014, DOI , TARA - Full Text
• Ní Cheallaigh, C., Sheedy, F.J., Harris, J., Muñoz-Wolf, N., Lee, J., West, K., McDermott, E.P., Smyth, A., Gleeson, L.E., Coleman, M., Martinez, N., Hearnden, C.H., Tynan, G.A., Carroll, E.C., Jones, S.A., Corr, S.C., Bernard, N.J., Hughes, M.M., Corcoran, S.E., O'Sullivan, M., Fallon, C.M., Kornfeld, H., Golenbock, D., Gordon, S.V., O'Neill, L.A., Keane, J. Lavelle, E.C, A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling., Immunity, 44, (2), 2016, p368 - 379Journal Article, 2016, URL , TARA - Full Text
• Lavelle, E.C., Grant, G., Pfuller,U. and O'Hagan, D.T, Type II ribosome-inactivating proteins from mistletoe are effective adjuvants when administered by mucosal and transcutaneous routes, Vaccine , Supplement 2, (S2), 2006Journal Article, 2006
• Lavelle, E.C., McGuirk, P. and Mills, K.H.G. , Molecules of Infectious Agents as Immunomodulatory Drugs, Current Medicinal Chemistry , 4, (5), 2004, p499 - 508Journal Article, 2004, URL
• Lavelle EC., Grant G., Pfuller U. and O'Hagan D.T, Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract, The Journal of Drug Targeting , 12, (2), 2004, p89 - 95Journal Article, 2004, DOI
• O'Hagan, D.T and Lavelle, E. , Novel adjuvants and delivery systems for HIV vaccines, AIDS, 16, 2002, pS115 - S124Journal Article, 2002
• Lavelle, E.C, Targeted delivery of drugs to the gastrointestinal tract, CRC Critical Reviews in Therapeutic Drug Carrier Systems, 18, (4), 2001, p341 - 386Journal Article, 2001
• Lavelle, E.C., Grant, G., Pusztai,A., Pfüller,U and O'Hagan, D.T. , The identification of plant lectins with mucosal adjuvant activity, Immunology, 102, (1), 2001, p77 - 86Journal Article, 2001, DOI
• Oleszycka, E., Moran, H.B.T., Tynan, G.A., Hearnden, C.H., Coutts, G., Campbell, M., Allan, S.M., Scott, C.J. and Lavelle, E.C. , IL-1α and inflammasome-independent IL-1β promote neutrophil infiltration following alum vaccination. , FEBS Journal, 283, (1), 2016, p9 - 24Journal Article, 2016, DOI
• Carroll, E.C., Jin, L., Mori, A., Muñoz-Wolf, N., Oleszycka, E., Moran, H.B.T., Mansouri, S., McEntee, C.P., Lambe, E., Agger, E.M., Andersen, P., Cunningham, C., Hertzog, P., Fitzgerald, K.A., Bowie, A.G., Lavelle, E.C., The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons, Immunity, 44, (3), 2016, p597 - 608Journal Article, 2016, DOI
• Lebre, F., Hearnden, C.H., Lavelle, E.C., Modulation of Immune Responses by Particulate Materials, Advanced Materials, 2016, 5525-5541Journal Article, 2016, DOI
• Schwartz, C., O'Grady, K., Lavelle, E.C., Fallon, P.G., Interleukin 33: An innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer, European Journal of Immunology, 46, (5), 2016, p1091-1100Journal Article, 2016, DOI
• Hughes, C.S., Colhoun, L.M., Bains, B.K., Kilgour, J.D., Burden, R.E., Burrows, J.F., Lavelle, E.C., Gilmore, B.F., Scott, C.J., Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophages, Particle and Fibre Toxicology, 13, (1), 2016, p19-Journal Article, 2016, DOI , TARA - Full Text
• Davitt, C.J.H., McNeela, E.A., Longet, S., Tobias, J., Aversa, V., McEntee, C.P., Rosa, M., Coulter, I.S., Holmgren, J., Lavelle, E.C., A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens, Journal of Controlled Release, 233, 2016, p162-173Journal Article, 2016, DOI
• Tivnan, A., Heilinger, T., Lavelle, E.C. and Prehn, J.H.M. , Advances in immunotherapy for the treatment of glioblastoma., Journal of Neuro-Oncology, 131, (1), 2017, p1-9Journal Article, 2017, DOI , TARA - Full Text
• Muñoz-Wolf N, Lavelle EC., Innate Immune Receptors., Methods Mol Biol., 1417, 2016, p1 - 43Journal Article, 2016, DOI
• Pandiyan P, Lavelle E.C, Editorial: Immune cells in the mucosa, Frontiers in Immunology, 7, (DEC), 2016, p00657-Journal Article, 2016, DOI , URL , TARA - Full Text
• Moore C., Movia D., Smith R., Hanlon D., Lebre F., Lavelle E., Byrne H., Coleman J., Volkov Y., McIntyre J., Industrial grade 2D molybdenum disulphide (MoS2): an in vitro exploration of the impact on cellular uptake, cytotoxicity, and inflammation, 2D Materials, 4, (2), 2017Journal Article, 2017, DOI , URL
• Lebre, F., Sridharan, R., Sawkins, M.J., Kelly, D.J., O'Brien, F.J. and Lavelle, E.C., The shape and size of hydroxyapatite particles dictate inflammatory responses following implantation, Scientific Reports, 7, (1), 2017, p2922 -Journal Article, 2017, DOI , URL , TARA - Full Text
• Longet, S., Aversa, V., O'Donnell, D., Tobias, J., Rosa, M., Holmgren, J., Coulter, I.S. and Lavelle, E.C., Thermostability of the coating, antigen and immunostimulator in an adjuvanted oral capsule vaccine formulation, International Journal of Pharmaceutics, 534, (1-2), 2017, p60-70Journal Article, 2017, DOI , URL
• Lundahl, M.L.E. and Scanlan, E.M. and Lavelle, E.C., Therapeutic potential of carbohydrates as regulators of macrophage activation, Biochemical Pharmacology, 146, 2017, p23-41Journal Article, 2017, DOI , URL
• Harte, C., Gorman, A.L., McCluskey, S., Carty, M., Bowie, A.G., Scott, C.J., Meade, K.G. and Lavelle, E.C., Alum activates the bovine NLRP3 inflammasome, Frontiers in Immunology, 8, 2017, p1494-Journal Article, 2017, DOI , URL
• Barnes, D.D. and Lundahl, M.L.E. and Lavelle, E.C. and Scanlan, E.M., The Emergence of Phenolic Glycans as Virulence Factors in Mycobacterium tuberculosis, ACS Chemical Biology, 12, (8), 2017, p1969-1979Journal Article, 2017, DOI , URL
• Munoz-Wolf, N. and Lavelle, E.C., Hippo interferes with antiviral defences, Nature Cell Biology, 19, (4), 2017, p267-269Journal Article, 2017, DOI , URL
• The Role of Inflammasomes in Adjuvant-Driven Humoral and Cellular Immune Responses in, editor(s)Virgil Schijns and Derek O'Hagan , Immunopotentiators in Modern Vaccines , 2016, pp23-42 , [Munoz-Wolf, N., McCluskey, S. and Lavelle, E.C.]Book Chapter, 2016, DOI , URL
• Lavelle, E.C. and Tomar, J., Mucosal vaccines, adjuvants and delivery 2016 - A meetings management conference, Drugs of the Future, 41, (11), 2016, p689-695Journal Article, 2016, DOI , URL
• Oleszycka, E., McCluskey, S., Sharp, F.A., Muñoz-Wolf, N., Hams, E., Gorman, A.L., Fallon, P.G. and Lavelle EC., The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses., European Journal of Immunology, 2018, 705-715Journal Article, 2018, DOI
• Longet S, Lundahl MLE, Lavelle EC., Targeted Strategies for Mucosal Vaccination., Bioconjugate Chemistry, 29, (3), 2018, p613 - 623Journal Article, 2018, DOI
• Clancy, D.M. and Sullivan, G.P. and Moran, H.B.T. and Henry, C.M. and Reeves, E.P. and McElvaney, N.G. and Lavelle, E.C. and Martin, S.J., Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing, Cell Reports, 22, (11), 2018, p2809-2817Journal Article, 2018, DOI , URL , TARA - Full Text
• Munoz-Wolf, N. and Lavelle, E.C., A Guide to IL-1 family cytokines in adjuvanticity, FEBS Journal, 285, (13), 2018, p2377 - 2401Journal Article, 2018, DOI , URL
• Lavelle, E.C. and McLachlan,J., Striking the right balance: using immunomodulators to target infectious diseases, cancer and autoimmunity, Current Opinion in Pharmacology, 41, 2018, pvii - ixJournal Article, 2018, DOI
• Moran, H.B.T., Turley, J., Andersen, M. and Lavelle, E.C , Immunomodulatory properties of chitosan polymers. , Biomaterials, 184, 2018, p1 - 9Journal Article, 2018, DOI
• Lebre, F., Pedroso de Lima, M.C., Lavelle, E.C. and Borges, O , Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles., International Journal of Pharmaceutics, 552, (112), 2018, p12 - 15Journal Article, 2018, DOI
• Lebre, F., Hanlon, D., Boland, J.B., Coleman, J. and Lavelle E.C. , Exfoliation in Endotoxin‐Free Albumin Generates Pristine Graphene with Reduced Inflammatory Properties., Advanced Biosystems, 2, (12), 2018, p1800102-Journal Article, 2018, DOI
• O'Grady, K., Hearnden, C.C.H., Bento, D., Oleszycka, E., Andersen, P., Muñoz-Wolf, N. and Lavelle, E.C. , IL-33 is a negative regulator of vaccine-induced antigen-specific cellular immunity, The Journal of Immunology, 2019Journal Article, 2019
• Nazmi, A., Field, R.H., Griffin, E.W., Haugh, O., Hennessy, E., Cox, D., Reis, R., Tortorelli, L., Murray, C.L., Lopez-Rodriguez, A.B., Lavelle, E.C., Dunne, A. and Cunningham,C. , Chronic neurodegeneration induces Type I interferon synthesis via STING, shaping microglial phenotype and accelerating disease progression, Glia, 67, 2019, p1254 - 1276Journal Article, 2019, DOI , TARA - Full Text
• Emma B. O'Connor, Natalia Muñoz-Wolf, Gemma Leon, Ed C. Lavelle, Kingston H. G. Mills, Patrick T. Walsh and Richard K. Porter, UCP3 reciprocally controls CD4+ Th17 and Treg cell differentiation, PLoS ONE, 15, (11), 2020, pe02-Journal Article, 2020, DOI , TARA - Full Text
• Innate immune receptors in, editor(s)Pablo Pelegrin and Francesco Di Virgilio , Nod Like Receptors, Springer, 2016, pp1-43 , [Muñoz-Wolf, N and Lavelle, E.C. ]Book Chapter, 2016
• Carty, M. and Kearney, J. and Shanahan, K.A. and Hams, E. and Sugisawa, R. and Connolly, D. and Doran, C.G. and Muñoz-Wolf, N. and GÃ"rtler, C. and Fitzgerald, K.A. and Lavelle, E.C. and Fallon, P.G. and Bowie, A.G., Cell Survival and Cytokine Release after Inflammasome Activation Is Regulated by the Toll-IL-1R Protein SARM, Immunity, 50, (6), 2019, p1412-1424.e6Journal Article, 2019, TARA - Full Text
• Davitt, C.J.H. and Longet, S. and Albutti, A. and Aversa, V. and Nordqvist, S. and Hackett, B. and McEntee, C.P. and Rosa, M. and Coulter, I.S. and Lebens, M. and Tobias, J. and Holmgren, J. and Lavelle, E.C., Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines, Mucosal Immunology, 12, (4), 2019, p1055-1064Journal Article, 2019, DOI , URL , TARA - Full Text
• Lebre, F. and Lavelle, E.C. and Borges, O., Easy and effective method to generate endotoxin-free chitosan particles for immunotoxicology and immunopharmacology studies, Journal of Pharmacy and Pharmacology, 71, (6), 2019, p920-928Journal Article, 2019, DOI , URL
• Liddicoat, A.M. and Lavelle, E.C., Modulation of innate immunity by cyclosporine A, Biochemical Pharmacology, 163, 2019, p472-480Journal Article, 2019, DOI , URL
• McEntee, C.P. and Finlay, C.M. and Lavelle, E.C., Divergent roles for the IL-1 family in gastrointestinal homeostasis and inflammation, Frontiers in Immunology, 10, (JUN), 2019Journal Article, 2019, DOI , URL , TARA - Full Text
• Jiménez, J.M. and Salazar, M.L. and Arancibia, S. and Villar, J. and Salazar, F. and Brown, G.D. and Lavelle, E.C. and Martínez-Pomares, L. and Ortiz-Quintero, J. and Lavandero, S. and Manubens, A. and Becker, M.I., TLR4, but neither dectin-1 nor dectin-2, participates in the mollusk hemocyanin-induced proinflammatory effects in antigen-presenting cells from mammals, Frontiers in Immunology, 10, (MAY), 2019Journal Article, 2019, DOI , URL , TARA - Full Text
• Lavelle, E.C. and McLachlan, J.B., Editorial overview: Immunomodulation: Striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity, Current Opinion in Pharmacology, 41, 2018, pvii-ixJournal Article, 2018, DOI , URL
• Sinéad Kenealy∗, Joan Manils∗, Mathilde Raverdeau Natalia Munoz-Wolf, Gillian Barber, Alex Liddicoat, Ed C.Lavelle Emma M.Creagh , Caspase-11 Mediated Cell Death Contributes to the Pathogenesis of Imiquimod-Induced Psoriasis, Journal of Investigative Dermatology, 2019, p2389 - 2393Journal Article, 2019, DOI , TARA - Full Text
• Longet, S. and Abautret-Daly, A. and Davitt, C.J.H. and McEntee, C.P. and Aversa, V. and Rosa, M. and Coulter, I.S. and Holmgren, J. and Raghavan, S. and Lavelle, E.C., An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses, npj Vaccines, 4, (1), 2019Journal Article, 2019, DOI , URL , TARA - Full Text
• Hackett, E.E., Charles-Messance, H., O'Leary, S.M., Gleeson, L.E., Muñoz-Wolf, N., Case, S., Wedderburn, A., Johnston, D.G.W., Williams, M.A., Smyth, A., Ouimet, M., Moore, K.J., Lavelle, E.C., Corr, S.C., Gordon, S.V., Keane, J., Sheedy, F.J., Mycobacterium tuberculosis Limits Host Glycolysis and IL-1ß by Restriction of PFK-M via MicroRNA-21, Cell Reports, 30, (1), 2020, p124-136.e4Journal Article, 2020, DOI , TARA - Full Text
• Z. Zas³ona , E. Flis, M.M. Wilk, R.G. Carroll, E.M. Palsson-McDermott, M.M. Hughes, C. Diskin, K. Banahan, D.G. Ryan, A. Hooftman, A. Misiak, J. Kearney, G. Lochnit, W. Bertrams, T. Greulich, B. Schmeck, O.J. McElvaney, K.H.G. Mills, E.C. Lavelle, M. Wygrecka, E.M. Creagh & L.A.J. O'Neill , Caspase-11 promotes allergic airway inflammation, Nature Communications, 2020Journal Article, 2020, URL , TARA - Full Text
• McEntee, C.P., Moran, H.B.T., Muñoz-Wolf, N., Liddicoat, A.M., Carroll, E.C., Erbo-Wern, J., Coulter, I.S., Andersen, P., Follmann, F. and Lavelle, E.C. (2020). , Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming. , Vaccine, 38, (3), 2020, p635 - 643Journal Article, 2020, DOI
• Shears, R.K., Jacques, L.C., Naylor, G., Miyashita, L., Khandaker, S., Lebre, F. and Lavelle, E.C., Grigg, J., French, N., Neill, D.R. and Kadioglu, A. , Exposure to diesel exhaust particles increases susceptibility to invasive pneumococcal disease. , J Allergy Clin Immunol., 145, (4), 2020, p1272 - 1284Journal Article, 2020, DOI
• Shears RK, Jacques LC, Naylor G, Miyashita L, Khandaker S, Lebre F, Lavelle EC, Grigg J, French N, Neill DR, Kadioglu A., Exposure to diesel exhaust particles increases susceptibility to invasive pneumococcal disease., The Journal of allergy and clinical immunology, 145, (4), 2020, p1272-1284.e6Journal Article, 2020, DOI , TARA - Full Text
• Lebre F, Boland JB, Gouveia P, Gorman AL, Lundahl MLE, I Lynch R, O'Brien FJ, Coleman J, Lavelle EC., Pristine graphene induces innate immune training., Nanoscale, 12, (20), 2020, p11192-11200Journal Article, 2020, DOI
• Schijns V, Lavelle EC., Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity., European journal of immunology, 2020Journal Article, 2020, DOI , TARA - Full Text
• Lemoine C, Thakur A, Kraji"nik D, Guyon R, Longet S, Razim A, Górska S, Panteli" I, Ili" T, Nikoli" I, Lavelle EC, Gamian A, Savi" S, Milicic A., Technological Approaches for Improving Vaccination Compliance and Coverage., Vaccines, 8, (2), 2020, pE304-Journal Article, 2020, DOI , TARA - Full Text
• Schijns, V., Fernández-Tejada, A., Barjaktarović, Z., Bouzalas, I., Brimnes, J., Chernysh, S., Gizurarson, S., Gursel, I., Jakopin, Z., Lawrenz, M., Nativi, C., Paul, S., Pedersen, G.K., Rosano, C., Ruiz-de-Angulo, A., Slütter, B., Thakur, A., Christensen, D. and Lavelle, E.C., Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. , Immunological Reviews , 2020Journal Article, 2020, TARA - Full Text
• Lavelle, E.C. and Carsetti, R. and Pickl, W.F. and Wiedermann, U., Editorial: Challenges in Vaccinology, Frontiers in Immunology, 11, (632537), 2020Journal Article, 2020, DOI , URL , TARA - Full Text
• Lundahl, M. and Lynch, D.M. and Barnes, D. and McSweeney, L. and Gorman, A. and Lebre, F. and Gordon, S.V. and Lavelle, E.C. and Scanlan, E.M., Mycobacterial para-Hydroxybenzoic Acid-Derivatives (pHBADs) and Related Structures Induce Macrophage Innate Memory, ACS Chemical Biology, 15, (9), 2020, p2415-2421Journal Article, 2020, DOI , URL
• Dowling JK, Afzal R, Gearing LJ, Cervantes-Silva MP, Annett S, Davis GM, De Santi C, Assmann N, Dettmer K, Gough DJ, Bantug GR, Hamid FI, Nally FK, Duffy CP, Gorman AL, Liddicoat AM, Lavelle EC, Hess C, Oefner PJ, Finlay DK, Davey GP, Robson T, Curtis AM, Hertzog PJ, Williams BRG, McCoy CE , Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophages, Nature Communications, 12, (1), 2021, p1460-Journal Article, 2021, DOI
• Turley, J.L. and Moran, H.B.T. and McEntee, C.P. and O'Grady, K. and Muñoz-Wolf, N. and Jin, L. and Follmann, F. and Andersen, P. and Andersson, M. and Lavelle, E.C., Chitin-derived polymer deacetylation regulates mitochondrial reactive oxygen species dependent cGAS-STING and NLRP3 inflammasome activation, Biomaterials, 275, (120961), 2021Journal Article, 2021, DOI
• Albutti, A. and Longet, S. and McEntee, C.P. and Quinn, S. and Liddicoat, A. and Rîmniceanu, C. and Lycke, N. and Lynch, L. and Cardell, S. and Lavelle, E.C., Type ii nkt cell agonist, sulfatide, is an effective adjuvant for oral heat-killed cholera vaccines, Vaccines, 9, (6), 2021Journal Article, 2021, DOI , URL , TARA - Full Text
• Scott, L.M. and Vincent, E.E. and Hudson, N. and Neal, C. and Jones, N. and Lavelle, E.C. and Campbell, M. and Halestrap, A.P. and Dick, A.D. and Theodoropoulou, S., Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors, JCI Insight, 6, (8), 2021Journal Article, 2021, DOI , URL , TARA - Full Text
• Lavelle, E.C. and Ward, R.W., Publisher Correction: Mucosal vaccines â€" fortifying the frontiers (Nature Reviews Immunology, (2021), 10.1038/s41577-021-00583-2), Nature Reviews Immunology, 2021Journal Article, 2021, DOI , URL
• Lavelle, E.C. and Ward, R.W., Mucosal vaccines â€" fortifying the frontiers, Nature Reviews Immunology, 2021Journal Article, 2021, DOI , URL
• Lynch RI, Lavelle EC., Immuno-modulatory biomaterials as anti-inflammatory therapeutics., Biochemical pharmacology, 197, 2022, p114890Journal Article, 2022, DOI
• Muñoz-Wolf N, Lavelle EC., Promotion of trained innate immunity by nanoparticles., Seminars in immunology, 2021, p101542Journal Article, 2021, DOI
• Turley JL, Lavelle EC., Fatballs foster fabulous follicles., Immunity, 54, (12), 2021, p2695-2697Journal Article, 2021, DOI
• Turley, J.L. and Lavelle, E.C., Resolving adjuvant mode of action to enhance vaccine efficacy, Current Opinion in Immunology, 77, (102229), 2022Journal Article, 2022, DOI , URL
• Sullivan, G.P. and Davidovich, P. and Muñoz-Wolf, N. and Ward, R.W. and Hernandez Santana, Y.E. and Clancy, D.M. and Gorman, A. and Najda, Z. and Turk, B. and Walsh, P.T. and Lavelle, E.C. and Martin, S.J., Myeloid cell-derived proteases produce a proinflammatory form of IL-37 that signals via IL-36 receptor engagement, Science immunology, 7, (78), 2022, peade5728Journal Article, 2022, DOI , TARA - Full Text
• Muñoz-Wolf, N. and Ward, R.W. and Hearnden, C.H. and Sharp, F.A. and Geoghegan, J. and O'Grady, K. and McEntee, C.P. and Shanahan, K.A. and Guy, C. and Bowie, A.G. and Campbell, M. and Roces, C.B. and Anderluzzi, G. and Webb, C. and Perrie, Y. and Creagh, E. and Lavelle, E.C., Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles, Cell Reports Medicine, 4, (1), 2023Journal Article, 2023, DOI
• Craig P. McEntee, Hannah B.T. Moran, Natalia Muñoz-Wolf, Alex M. Liddicoat, Elizabeth C. Carroll, Jeanette Erbo-Wern, Ivan S. Coulter, Peter Andersen, Frank Follmann, Ed C. Lavelle, Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming, Vaccine, 38, (3), 2020, p635--643Journal Article, 2020
• Mimmi Lundahl, Dylan M. Lynch, Danielle Barnes, Lauren McSweeney, Aoife Gorman, Filipa Lebre, Stephen V. Gordon, Ed C. Lavelle, Eoin M. Scanlan, Mycobacterial para-Hydroxybenzoic Acid-Derivatives (pHBADs) and Related Structures Induce Macrophage Innate Memory, ACS Chemical Biology, 2020Journal Article, 2020
• Alex M. Liddicoat, Ed C. Lavelle, Modulation of innate immunity by cyclosporine A, Biochemical Pharmacology, 2019Journal Article, 2019
• F. Lebre, M.C. Pedroso de Lima, Ed C. Lavelle, O. Borges, Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles, International Journal of Pharmaceutics, 2018Journal Article, 2018
• Filipa Lebre, Damien Hanlon, John B. Boland, Jonathan Coleman, Ed C. Lavelle, Exfoliation in Endotoxin"Free Albumin Generates Pristine Graphene with Reduced Inflammatory Properties, Advanced Biosystems, 2018, p1800102Journal Article, 2018
• Oleszycka, E., Lavelle, E.C., Immunomodulatory properties of the vaccine adjuvant alum, Current Opinion in Immunology, 28, (1), 2014, p1-5Journal Article, 2014
• Bourke, J., Brereton, C.F., Gordon, S.V., Lavelle, E.C., Scanlan, E.M., The synthesis and biological evaluation of mycobacterial p-hydroxybenzoic acid derivatives (p-HBADs), Organic and Biomolecular Chemistry, 12, (7), 2014, p1114-1123Journal Article, 2014
• Hearnden, C., Lavelle, E.C., Adjuvant Strategies for Vaccines: The Use of Adjuvants within the Cancer Vaccine Setting, Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition, 2013, p333-349Journal Article, 2013
• Yang, M., Flavin, K., Kopf, I., Radics, G., Hearnden, C.H.A., McManus, G.J., Moran, B., Villalta-Cerdas, A., Echegoyen, L.A., Giordani, S., Lavelle, E.C., Functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation, Small, 9, (24), 2013, p4194-4206Journal Article, 2013
• Yang, M., Hearnden, C.H.A., Oleszycka, E., Lavelle, E.C., NLRP3 inflammasome activation and cytotoxicity induced by particulate adjuvants, Methods in Molecular Biology, 1040, 2013, p41-63Journal Article, 2013
• Tynan, G.A., McNaughton, A., Jarnicki, A., Tsuji, T., Lavelle, E.C., Polymyxin B inadequately quenches the effects of contaminating lipopolysaccharide on murine dendritic cells, PLoS ONE, 7, (5), 2012Journal Article, 2012
• McNeela, E.A., Lavelle, E.C., Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination, Current Topics in Microbiology and Immunology, 354, (1), 2012, p75-99Journal Article, 2012
• Huete-Carrasco J, Lavelle EC., Immunostimulatory nanoparticles go viral., Nature materials, 22, (3), 2023, p273-275Journal Article, 2023, DOI
• Oleszycka E, O'Brien EC, Freeley M, Lavelle EC, Long A., Bile acids induce IL-1" and drive NLRP3 inflammasome-independent production of IL-1ß in murine dendritic cells., Frontiers in immunology, 14, 2023, p1285357Journal Article, 2023, DOI
• Lavelle, E.C., Grant, G., Pusztai,A., Pfüller,U and O'Hagan, D.T. , Mucosal immunogenicity of plant lectins in mice., Immunology, 99, (1), 2000, p30 - 37Journal Article, 2000, DOI
• Lavelle E.C, Patent update on drug delivery: January-June, Expert Opinion on Therapeutic Patents , 10, (9), 2000, p1335 - 1343Journal Article, 2000
• Lavelle E.C, Targeted mucosal delivery of drugs and vaccines, Expert Opinion on Therapeutic Patents , 10, (2), 2000, p179 - 190Journal Article, 2000, DOI
• Gill, I.J., Lin,W., Jenkins,P., Watts,P., Jiminez,M., Illum,L., Davis,S.S., Wood,J.M., Major,D., Minor,P.D., Li,X., Lavelle,E.C. and Coombes,A.G.A. , Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines, Vaccine, 18, (3-4), 2000, p238 - 250Journal Article, 2000, DOI
• Lavelle, E.C., Yeh, M.K., Coombes, A.G.A. and Davis, S.S., The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. , Vaccine, 17, (6), 1999, p512 - 529Journal Article, 1999, DOI
• Delgado, A., Lavelle, E.C., Hartshorne,M. and Davis, S.S. , PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. , Vaccine, 12, (22), 1999, p2927 - 2938Journal Article, 1999, DOI
• Coombes, A.G.A., Lavelle,E.C. and Davis, S.S. , Biodegradable lamellar particles of poly (lactide) induce sustained immune responses to a single dose of adsorbed protein. , Vaccine, 17, (19), 1999, p2410 - 2422Journal Article, 1999, DOI
• Takahata, H., Lavelle, E.C., Coombes, A.G.A., Rafati, H. and Davis, S.S. , An investigation into the effects of exposure to digestive enzymes and polymer degradation on the integrity of microparticle-associated antigen. , The Journal of Controlled Release , 50, (1-3), 1998, p237 - 248Journal Article, 1998
• Coombes, A.G.A., Yeh, M-K., Lavelle, E.C. and Davis, S.S. , The control of protein release from poly (DL lactide-co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. , The Journal of Controlled Release, 52, (3), 1998, p311 - 320Journal Article, 1998, DOI
• Lavelle, E.C., Jenkins, P.G. and Harris, J.E. , Oral immunisation of rainbow trout with antigen microencapsulated in PLG microparticles. , Vaccine, 15, (10), 1997, p1070 - 1078Journal Article, 1997, DOI
• Lavelle, E. C. and Harris, J. E. , The proteolysis of an orally administered protein antigen in the digestive tract of rainbow trout, Oncorhynchus mykiss (Walbaum,1792). , Comparative Biochemistry and Physiology, 117, (2), 1997, p263 - 275Journal Article, 1997
• Rafati, H., Lavelle, E.C., Coombes, A.G.A., Stolnik, S., Holland, J. and Davis, S.S., The immune response to a model antigen associated with PLG microparticles prepared using different surfactants, Vaccine, 15, (17-18), 1996, p1888 - 1897Journal Article, 1996, DOI
• Coombes, A.G.A., Lavelle, E.C., Jenkins, P. G. and Davis, S. S. , Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen, Vaccine, 14, (14), 1996, p1429 - 1438Journal Article, 1996, DOI
• Coombes, A.G.A., Lavelle, E.C., Jenkins, P. G., Holland, J. and Davis, S. S. , Biodegradable microparticles as parenteral vaccine delivery systems. , Developments in Biological Standardization , 87, 1996, p231-Journal Article, 1996
• Thomas, N. W., Jenkins, P.G., Howard, K.A., Smith, M.W., Lavelle, E.C., Holland,J. and Davis, S.S. , Particle uptake and translocation across epithelial membranes, The Journal of Anatomy, 189, (3), 1996, p487 - 490Journal Article, 1996, URL
• Lavelle, E.C., Sharif, S., Thomas, N. W., Holland, J. and Davis, S. S. , The importance of gastrointestinal uptake of particles in the design of oral delivery systems. , Advanced Drug Delivery Reviews, 18, (1), 1995, p5 - 22Journal Article, 1995, DOI
• Joanna L. Turley, Ross W. Ward, Jorge Huete-Carrasco, Natalia Muñoz-Wolf, Kate Roche, Lei Jin, Andrew Bowie, Mats Andersson, Ed Lavelle, Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8+ T cell-dependent anti-tumor immunity, Cell Reports Medicine, 5, (5), 2024, p101560Journal Article, 2024
• Ed C. Lavelle, Craig P. McEntee, Vaccine adjuvants: Tailoring innate recognition to send the right message, Immunity, 57, (4), 2024, p772-789Journal Article, 2024
• Jorge Huete"Carrasco, Roisin I. Lynch, Ross W. Ward, Ed C. Lavelle, Rational design of polymer"based particulate vaccine adjuvants, European Journal of Immunology, 54, (2), 2024Journal Article, 2024
• Lavelle, E.C. and Genescà, M., Editorial overview: The march of mucosal vaccines, Current Opinion in Immunology, 86, (102408), 2024Journal Article, 2024, DOI , URL
• Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KHG, Proinflammatory Responses in the Murine Brain after Intranasal Delivery of Cholera Toxin: Implications for the Use of AB Toxins as Adjuvants in Intranasal Vaccines, Journal of Infectious Diseases, 192, (9), 2005, p1628 - 1633Journal Article, 2005, DOI , URL , TARA - Full Text
• Lavelle, E.C, Generation of improved mucosal vaccines by induction of innate immunity., Cellular And Molecular Life Sciences, 62, (23), 2005, p2750-2770Journal Article, 2005, DOI
• Boyd, A.P., Ross, P.J., Conroy, H., Mahon, N Lavelle, E.C.and Mills, K.H.G., Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death, Journal of Immunology, 175, 2005, p730 - 738Journal Article, 2005, URL , TARA - Full Text
• Lavelle EC, Lectins and microparticles for enhanced oral vaccination, Methods, 38, (2), 2006, p84 - 89Journal Article, 2006
• Sutton, C., Brereton, C., Keogh, B., Mills, K.H.G. Lavelle, E.C., A crucial role for IL-1 in the induction of IL-17 producing T cells that mediate autoimmune encephalomyelitis, The Journal of Experimental Medicine, 203, (7), 2006, p1685 - 1691Journal Article, 2006, DOI , URL
• Higgins, S., Jarnicki, A, Lavelle, E.C. and Mills, K.H.G, TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells, The Journal of Immunology, 177, 2006, p7980 - 7989Journal Article, 2006, URL , TARA - Full Text
• Lavelle EC, Grant G, Pusztai A, Pfüller U, Leavy O, McNeela E, Mills KH, O'Hagan DT., Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2., Journal of Immunology, 107, (2), 2002, p268 - 274Journal Article, 2002, DOI , TARA - Full Text
• Jarnicki, AJ, Conroy, H. Brereton, C, Donnelly, G., Toomey, D., Walsh, K.,, Sweeney, C., Leavy, O., Fletcher, J., Lavelle, E., Dunne, P. and Mills, K.H.G., Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics, Journal of Immunology, 180, (6), 2008, p3797 - 3806Journal Article, 2008, DOI , URL , TARA - Full Text
• Lavelle, E.C. and O'Hagan, D.T, Delivery systems and adjuvants for oral vaccines, Expert Opinion on Drug Delivery , 3, (6), 2006, p747 - 762Journal Article, 2006, DOI
• Harris, J., Hope, J. and Lavelle, E.C. , Autophagy and the immune response to TB, Transboundary and Emerging Diseases , 56, (6-7), 2009, p248-254Journal Article, 2009, DOI
• Lavelle, E.C., Thanavala, J. and Ogra,P. , Mucosal immunity on the banks of the Duoro, Human Vaccines, 5, (5), 2009, p1 - 3Journal Article, 2009, URL
• Thanavala,Y., Lavelle, EC. and Ogra,P. , All things mucosal, Expert Reviews in Vaccines , 8, (2), 2009, p139 - 142Journal Article, 2009, DOI
• Alexander U. Lüthi, Sean P. Cullen, Edel A. McNeela, Patrick J. Duriez, Inna S. Afonina, Clare Sheridan, Gabriela Brumatti, Rebecca C. Taylor, Kristof Kersse, Peter Vandenabeele, Ed C. Lavelle, and Seamus J. Martin, Suppression of Interleukin-33 Bioactivity through Proteolysis by Apoptotic Caspases, Immunity, 31, (1), 2009, p84-98Journal Article, 2009, DOI , TARA - Full Text
• Sharp, F., Ruane, D., Claas, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O'Hagan, D.T., Pétrilli, V., Tschopp, J., O'Neill, L.A.J. and *Lavelle, E.C, Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome., Proceedings of the National Academy of Sciences of the U.S.A, 106, (3), 2009, p870-875Journal Article, 2009, DOI , TARA - Full Text
• Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH., Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease., Journal of Immunology, 183, (3), 2009, p1715-2173Journal Article, 2009, DOI , TARA - Full Text
• Sutton, C.E., Lalor, S.J., Sweeney, C.M., Brereton, C.F., Lavelle, E.C. and Mills, K.H.G , Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity., Immunity, 31, (2), 2009, p331-341Journal Article, 2009, DOI , TARA - Full Text
• Lavelle E.C., Evaluation of the binding, uptake and immune responses elicited to orally administered lectins and microparticles, Methods , 38, (2), 2006, p84-89Journal Article, 2006
• Jenkins, P.G., Barton, R.N., Harris, J.E., Lavelle, E.C. and Wrathmell, A.B. , Enhanced delivery systems for enteric antigen uptake in teleosts, Vaccine, 10, 1992, p281-282Journal Article, 1992
• Coombes, A.G.A., Lavelle, E.C., Jenkins, P.G. and Davis, S.S., Pulsed and sustained immune responses following a single dose of a model antigen associated with resorbable microparticles, Proceedings of International Symposium on the Controlled Release of Bioactive Materials. , 226-230, 1995, p560-561Journal Article, 1995
• Discovery of vaccine adjuvants in, editor(s)Editor Shane C. Gad. , Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing., John Wiley & Sons , 2011, pp1 - 14, [Sharp, F. and Lavelle, E.C.]Book Chapter, 2011
• Oral delivery of vaccines in, editor(s)J Fix. and V H.L. Lee , Oral Peptide and Protein Drug Delivery, New York , Marcel Dekker, 2009, [Lavelle, E.C. and O'Hagan, D.T.]Book Chapter, 2009
• Modified bacterial toxins in, editor(s)Charles J Hackett & Donald A Harn Jr, , Vaccine Adjuvants: Immunological and Clinical Principles., Publisher Humana, 2005, pp296 , [Lavelle EC., Leavy O. Mills KHG. ]Book Chapter, 2005
• Lectins in oral vaccination. in, editor(s)Eds, S. Bardocz., G. Hajós and A. Pusztai , COST 98-Effects of antinutrients on the nutritional value of legume diets., European Commission., 1999, pp148-159. , [Lavelle,E.C ]Book Chapter, 1999
• Lavelle, E.C., Chiron Corporation, Plant lectins as mucosal adjuvants. , 2001, WO0134193Patent, 2001
• Mills, K.H.G., Boyd, A.P., Ross, P.J. and Lavelle, EC., , CyaA in the prophylaxis/treatment of inflammatory and immune-mediated disorders., 2003Patent, 2003
• Mills, K.H.G., Higgins, S.H and Lavelle, E.C. , Tracheal Cytotoxin/ "Methods and compositions for modulating and immune response, 2006Patent, 2006
• Lavelle EC, Murphy C, O'Neill LA, Creagh EM, The role of TLRs, NLRs and RLRs in mucosal innate immunity and homeostasis , Mucosal Immunology, 3, (1), 2010, p17 - 28Journal Article, 2010, DOI , URL
• McNeela, E.A. and Lavelle, E.C. , Recent advances in microparticles and nanoparticles for mucosal vaccination , Current Topics in Microbiology and Immunology, 354, 2012, p75-99Journal Article, 2012, DOI
• Harris, J., Sharp, F.A. and Lavelle, E.C, The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants , European Journal of Immunology , 40, (3), 2010, p634-638Journal Article, 2010, DOI
• Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH., Response: Characteristics of IL-17-Producing gammadelta T Cells., Immunity, 32, (1), 2010, p3 - 4Journal Article, 2010, DOI
• Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., Becker, C., Lavelle,E.C. and O'Neill, L.A.J., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β 2 in type 2 diabetes , Nature Immunology, 11, (10), 2010, p897-904Journal Article, 2010, DOI
• Harris, J..Hartman, M., Roche, C., Zeng, S.G., O'Shea, A., Sharp, F.A., Lambe, E.M., Creagh, E.M., Golenbock, D.T., Tschopp, J., Kornfeld, H., Fitzgerald, K.A. and Lavelle, E.C , Autophagy controls IL-1ß secretion by targeting pro-IL-1ß for degradation, The Journal of Biological Chemistry, 286, 2011, p9587 - 9597Journal Article, 2011, DOI , URL , TARA - Full Text
• Ní Cheallaigh C, Keane J, Lavelle EC, Hope JC, Harris J., Autophagy in the immune response to tuberculosis: clinical perspectives., Clinical and Experimental Immunology, 164, (3), 2011, p291 - 300Journal Article, 2011, DOI , TARA - Full Text
• McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, Moran B, Fitzgerald KA, Tschopp J, Pétrilli V, Andrew PW, Kadioglu A, Lavelle EC, Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4., PLoS pathogens, 6, (11), 2010, pe1001191Journal Article, 2010, DOI , URL , TARA - Full Text
• Brereton, C.F., Sutton, C.E., Ross, P.J., Iwakura, Y., Pizza, M., Rappuoli, R., Lavelle, E.C., Mills, K.H.G., Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production, Journal of Immunology, 186, (10), 2011, p5896-5906Journal Article, 2011, DOI
• Ruane D.T and Lavelle E.C. , The role of CD103+ dendritic cells in the intestinal mucosal immune system. , Frontiers in Immunology , 2, 2011, p25Journal Article, 2011, DOI
• Afonina, I.S., Tynan, G.A., Logue, S. E., Cullen, S.P., Bots, M., Lüthi, A.U., Reeves, E.P., McElvaney, N.G., Medema, J.P., Lavelle, E.C. and Martin, S.J., Granzyme B-dependent proteolysis acts as a switch to enhance the pro-inflammatory activity of IL-1, Molecular Cell, 44, (2), 2011, p465 - 478Journal Article, 2011, DOI , TARA - Full Text
• Schijns,V.E.J.C and Lavelle, E.C, Trends in vaccine adjuvants. , Expert Reviews in Vaccines., 10, (4), 2011, p539 - 550Journal Article, 2011
• Lavelle, E.C., McNaughton, A. and McNeela, E.A., NLRP3 in protective immunity and vaccination against respiratory infection, Expert Review of Vaccines, 10, (3), 2011, p255 - 257Journal Article, 2011, DOI
• Rationales for including adjuvants in vaccines in, editor(s)Duc Hong Le , Novel Immunologic Adjuvants, Future Medicine Ltd, 2011, pp6 - 14, [Schijns, V.E.J.C. and Lavelle, E.C]Book Chapter, 2011, DOI
• Future Trends of Novel Vaccine Adjuvants in, editor(s)Duc Hong Le, E , Immunologic Adjuvants, Future Science Group, 2011, pp104 - 116, [Schijns, V.E.J.C. and Lavelle, E.C]Book Chapter, 2011, DOI
• Immunostimulatory properties of biodegradable microparticles in, editor(s)John H. Morrow, Clint Schmidt, Nadeem Sheikh, Huw Davies , Vaccinology: Principles and Practice., Wiley-Blackwell, 2012, [Sharp, F.A. and Lavelle, E.C ]Book Chapter, 2012
• Lavelle, E., McNeela, E., Armstrong, M., Leavy, O., Higgins, S.C. and Mills K.H.G., Cholera toxin promotes the induction of regulatory T cells by modulation dendritic cell activation, The Journal of Immunology, 171, 2003, p2384 - 2392Journal Article, 2003, URL , TARA - Full Text
• Higgins, S., Lavelle, E., McCann, C., Keogh, B., McNeela, E, Byrne, P., O'Gorman, B., Jarnicki, A., McGuirk, P. and Mills, K.H.G., Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology, Journal of Immunology, 171, (6), 2003, p3119 - 3127Journal Article, 2003, URL , TARA - Full Text
• Lavelle, E., McGuirk and Mills, K.H.G., Molecules of infectious agents as immunomodulatory drugs, Current Topics in Med. Chem., 4, (5), 2004, p499 - 508Journal Article, 2004, URL
• Ross, P.J., Lavelle, E.C., Mills, K.H.G. and A.P. Boyd., Adenylate cyclase toxin from Bordetella pertussis synergises with lipopolysaccharide to promote innate IL-10 production and enhance the induction of Th2 and regulatory T cells, Infection and Immunity, 72, (3), 2004, p1568 - 1579Journal Article, 2004, DOI , TARA - Full Text
• Bowe, F., Lavelle, E.C., McNeela, E. A., Hale, C., Clare, S., Arico, B., Giuliani, M.M., Rae, A., Huett, A., Rappuoli, R., Dougan, G. and Mills, K. H.G., Mucosal vaccination against serogroup B meningococcus:Induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin, Infection and Immunity, 72, (7), 2004, p4052 - 4060Journal Article, 2004, DOI , TARA - Full Text
• Lavelle EC, Jarnicki A, McNeela E, Armstrong ME, Higgins SC, Leavy O, Mills KHG, Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent, Journal of Leukocyte Biology, 75, (5), 2004, p756 - 763Journal Article, 2004, DOI , TARA - Full Text
• Cunningham CC, Mills E, Mielke LA, O'Farrell LK, Lavelle E, Mori A, McCarthy GM, Mills KH, Dunne A, Osteoarthritis-associated basic calcium phosphate crystals induce pro-inflammatory cytokines and damage-associated molecules via activation of Syk and PI3 kinase., Clinical immunology (Orlando, Fla.), 144, (3), 2012, p228-236Journal Article, 2012, DOI
• Peral de Castro C, Jones SA, Ní Cheallaigh C, Hearnden CA, Williams L, Winter J, Lavelle EC, Mills KH, Harris J, Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion., Journal of immunology (Baltimore, Md. : 1950), 189, (8), 2012, p4144-4153Journal Article, 2012, DOI
• Kearney CJ, Sheridan C, Cullen SP, Tynan GA, Logue SE, Afonina IS, Vucic D, Lavelle EC, Martin SJ, Inhibitor of Apoptosis Proteins (IAPs) and Their Antagonists Regulate Spontaneous and Tumor Necrosis Factor (TNF)-induced Proinflammatory Cytokine and Chemokine Production., The Journal of biological chemistry, 288, (7), 2013, p4878-4890Journal Article, 2013, DOI , TARA - Full Text
• Cullen SP, Henry CM, Kearney CJ, Logue SE, Feoktistova M, Tynan GA, Lavelle EC, Leverkus M, Martin SJ, Fas/CD95-Induced Chemokines Can Serve as "Find-Me" Signals for Apoptotic Cells., Molecular cell, 49, 2013, p1-15Journal Article, 2013, DOI , TARA - Full Text
• Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC, O'Neill LA, Hollyfield JG, Humphries P, NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components., Nature medicine, 18, (5), 2012, p791-798Journal Article, 2012, DOI
• Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH, Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine., PLoS pathogens, 9, (4), 2013, pe1003264Journal Article, 2013, DOI , TARA - Full Text
• Maher BM, Mulcahy ME, Murphy AG, Wilk M, O'Keeffe KM, Geoghegan JA, Lavelle EC, McLoughlin RM, Nlrp-3-driven interleukin 17 production by γδT cells controls infection outcomes during Staphylococcus aureus surgical site infection., Infection and immunity, 81, (12), 2013, p4478-4489Journal Article, 2013, DOI
• Campbell*, M, Doyle*, SL, Ozaki, E, Salomon, RG, Mori, A, Kenna, PF, Kiang, AS, Humphries, MM, Lavelle, EC, O'Neill, LAJ, Hollyfield, JG, and Humphries, P, NLRP3 plays a protective role during the development of age related macular degeneration through the induction of IL-18 by drusen components., Nature Medicine, 18, (5), 2012, p791 - 798Journal Article, 2012, DOI
• Misstear K, McNeela EA, Murphy AG, Geoghegan JA, O'Keeffe KM, Fox J, Chan K, Heuking S, Collin N, Foster TJ, McLoughlin RM, Lavelle EC, Targeted nasal vaccination provides antibody independent protection against Staphylococcus aureus., The Journal of infectious diseases, 209, (9), 2014, p1479-1484Journal Article, 2014, DOI , TARA - Full Text
• Yang, M., Flavin, K., Kopf, I., Radics, G., Hearnden, C.H.A., McManus, G.J., Moran, B., Villalta-Cerdas, A., Echegoyen, L.A., Giordani, S. and Lavelle, E.C. , Chemical surface functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation, Small, 9, (24), 2013, p4194 - 4206Journal Article, 2013
• Oleszycka, E. and Lavelle, E.C, The immunomodulatory properties of the vaccine adjuvant alum., Current Opinion in Immunology, 28C, 2014, p1 - 5Journal Article, 2014, DOI
• Arancibia, S., Espinoza, C., Salazar, F., Del Campo, M., Tampe, R., Zhong, T-Y., De Ioannes, P., Moltedo, B., Ferreira, J., Lavelle, E.C., Manubens, A., De Ioannes, A.E. and Becker, M.I., A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata exhibits outstanding anti-tumor activity in melanoma., PLoS One, 9, (1), 2014, pe87240Journal Article, 2014, DOI , TARA - Full Text
• Adjuvant Strategies in Vaccines. in, editor(s)Prendergast/Jaffee , Cancer Immunotherapy: Immune Suppression and Tumor Growth, Academic Press, 2013, pp333-349 , [Hearnden, C and Lavelle, E.C.]Book Chapter, 2013
• Ruane, DT., Brane, L., Reis, B., Cheong, C., Poles, J., Do, Y., Zhu, H., Velinzon, K., Choi, J-H., Studt, N., Mayer, L., Lavelle, E.C., Steinman, R., Mucida, D and Mehandru, S. , Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract., The Journal of Experimental Medicine, 210, (9), 2013, p1871-1888Journal Article, 2013, DOI , TARA - Full Text
• Bourke J, Brereton CF, Gordon SV, Lavelle EC and Scanlan EM, The Synthesis and Biological Evaluation of Mycobacterial p-Hydroxybenzoic Acid Derivatives (p-HBADs), Organic & Biomolecular Chemistry, 12, (7), 2014, p1114-1123Journal Article, 2014, TARA - Full Text
• Mori, A., Oleszycka, E., Sharp, F.A., Coleman, M., Ozasa, Y., Singh, M., O'Hagan, D.T., Tajber, L., Corrigan, O.I., McNeela, E.A., Lavelle, E.C., The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses, European Journal of Immunology, 42, (10), 2012, p2709-2719Journal Article, 2012, DOI
• Ismail M. Meraza, Claire H.A Hearnden, Xuewu Liua, Marie Yang, Laura Williams, Jianhua Gua, Jessica R. Rhudy, Kenji Yokoi, Ed C. Lavelle and Rita E. Serda , Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization increasing the anti-tumor efficacy of doxorubicin nanoliposomes, PLoS One, 2014, p0094703-Journal Article, 2014, DOI , TARA - Full Text
• Tynan GA, Hearnden CH, Oleszycka E, Lyons CL, Coutts G, O'Connell J, Corrigan MA, Lynch L, Campbell M, Callanan JJ, Mok KH, Geoghegan J, O'Farrelly C, Allan SM, Roche HM, O'Shea DB, Lavelle EC, Endogenous oils derived from human adipocytes are potent adjuvants that promote IL-1 alpha-dependent inflammation., Diabetes, 63, (3), 2014, p2037-2050Journal Article, 2014, DOI , TARA - Full Text
• Doyle, SL, Ozaki, E, Brennan, K, Humphries, MM, Mulfaul, K, Keaney, J, Kenna, PF, Maminishkis, A, Kiang, AS, Saunders, SP, Hams, E, Lavelle, EC, Gardiner, C, Fallon, PG, Adamson, P, Humphries, P, Campbell, M, IL-18 Attenuates Experimental Choroidal Neovascularization as a Potential Therapy for Wet Age-Related Macular Degeneration, SCIENCE TRANSLATIONAL MEDICINE, 6, 2014, p230-Journal Article, 2014, DOI , TARA - Full Text
• Tynan, GA, Hearnden, CH, Oleszycka, E, Lyons, CL, Coutts, G, O'Connell, J, Corrigan, MA, Lynch, L, Campbell, M, Callanan, JJ, Mok, KH, Geoghegan, J, O'Farrelly, C, Allan, SM, Roche, HM, O'Shea, DB, Lavelle, EC, Endogenous Oils Derived From Human Adipocytes Are Potent Adjuvants That Promote IL-1 alpha-Dependent Inflammation, Diabetes, 63, (6), 2014, p2037-2050Journal Article, 2014, DOI , TARA - Full Text
• Doyle SL, Ozaki E, Brennan K, Humphries MM, Mulfaul K, Keaney J, Kenna PF, Maminishkis A, Kiang AS, Saunders SP, Hams E, Lavelle EC, Gardiner C, Fallon PG, Adamson P, Humphries P, Campbell M, IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration., Science translational medicine, 6, (230), 2014, p230ra44Journal Article, 2014, DOI , TARA - Full Text
• Abautret-Daly AE, Davitt CJ, Lavelle EC, Harnessing the antibacterial and immunological properties of mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections., Biochemical pharmacology, 92, (2), 2014, p173-83Journal Article, 2014, DOI , TARA - Full Text

I am an internationally recognised leader in the field of vaccine adjuvants with a record of publishing high impact papers, attracting competitive research funding, generating and protecting intellectual property, engaging industrial partners and the public, organising conferences and adopting advisory roles. Adjuvants are essential components of vaccines that can profoundly enhance protective immune responses and specifically can affect the magnitude and type of vaccine -induced innate and adaptive immunity. My research is principally focused on how vaccine adjuvants enhance protective immune responses against infection and cancer. My group has made key discoveries that enhance our understanding of how the physicochemical properties of adjuvants influence the induction of innate and adaptive immunity. We have provided major new insights into how adjuvants engage innate cellular sensing pathways, particularly DNA sensing pathways and inflammasomes, pursuing the specific roles of interferons and cytokines of the IL-1 family in adjuvanticity. We have developed novel particulate vaccine adjuvants (IP filed, new start up in cancer vaccines launched - AilseVax). We have worked on developing an effective oral delivery system that has significant potential for vaccines against ETEC, cholera and Helicobacter pylori. The expertise we have developed in assessing particulate adjuvant regulation of immune responses also has relevance in the field of biomaterial interaction with the immune system. As a result, I have a substantial research programme in this area as part of the AMBER centre. Being a CRANN PI and an AMBER funded investigator has led to close connections with colleagues in Bioengineering, Chemistry and Physics and this cross-disciplinary dimension places my research in a unique position within Ireland. This allows me to pursue how particulate materials can regulate immune responses and how fundamental understanding of the underlying processes can help us to rationally design novel vaccine adjuvant systems but also enhanced biomaterials. My work at Trinity has been transformational over the past 17 years in establishing that nonmicrobial particulate adjuvants can be designed to activate specific innate sensing and signalling pathways and that this can be harnessed to induce and direct adaptive immune responses. This has led to publications in the leading journals in the field, many since my last promotion in 2015. The impact of my work can be seen in invitations to speak at the leading meetings in the field (111 invited conference talks and seminars since 2004), to serve on scientific advisory boards for conferences (15), to serve as chair on the advisory board of a vaccine centre in the U.K., to act as a consultant for leading (Merck, GSK, HIPRA) vaccine companies, to write reviews, commentaries and editorials and to serve as a panel member for prestigious grant agencies (e.g. Gates Foundation, German Centres of Excellence Programme). Being recognised as an authority in vaccine adjuvant research together with the global prominence of this field makes it likely that my influence will grow, generating many new research opportunities over the coming years.

• Title

  Immunomodulatory properties of nanoparticulates.
  Summary

  12 month project focusing on carbon based nanoparticles. Time commitment 4%.
  Date From

  2011
• Title

  Mechanism of action of chitin derived polymers
  Summary
  Funding Agency

  Trinity College Dublin
  Date From

  1-9-2017
  Date To

  1-9-2021
• Title

  Does Epac mediate a cyclic AMP-inducible pathway in dendritic cells that promotes pro-inflammatory T cell responses?
  Summary

  proposal ID: 07/RFP/BICF537. Principal Investigator.
  Funding Agency

  Science Foundation Ireland
  Date From

  2007
  Date To

  2010
• Title

  Improving vaccine responses in the paediatric population by harnessing cytosolic nucleic acid sensing responses to promote Th1 and Th17 cell polarisation
  Summary

  Co-PI with Dr Sarah Doyle.
  Funding Agency

  National Childrens Research Centre
  Date From

  1-1-2017
  Date To

  31-12-2019
• Title

  Targeting innate lymphoid cells in oral vaccination
  Summary
  Funding Agency

  Saudi Arabian Government/Saudi Arabian Cultural Bureau.
  Date From

  1-3-2015
  Date To

  28-2-2019
• Title

  Mode of action of oral vaccine adjuvants
  Summary

  FNS P300PB_164740
  Funding Agency

  Swiss National Science Foundation (SNSF)
  Date From

  1-2-2016
  Date To

  31-1-2019
• Title

  Investigating the Mal-IFN-γ axis as a determinant of morbidity and mortality in pneumococcal disease.
  Summary

  IRC award to Dr Natalia Munoz-Wolf.
  Funding Agency

  Irish Research Council
  Date From

  1-10-2017
  Date To

  31-9-2019
• Title

  Irish Society for Immunology meeting 2017
  Summary
  Funding Agency

  Science Foundation Ireland (SFI)
  Date From

  2017
  Date To

  2017
• Title

  Mechanism of action of alum as a vaccine adjuvant.
  Summary

  Summary: Investigation of the mechanisms by which alum activates and polarizes T cell responses, focusing on its effects on dendritic cells. Principal Investigator.
  Funding Agency

  Irish Research Council for Science, Engineering and Technology
  Date From

  2006
  Date To

  2009
• Title

  Innate immune training: a memorable encounter with adjuvants
  Summary

  Project ID GOIPG/2015/4023. Aoife Gorman.
  Funding Agency

  Irish Research Council
  Date From

  1-10-2015
  Date To

  31-9-2019
• Title

  Targeted delivery of particulate vaccine adjuvants. (2011).
  Summary

  EPSPG/2012/404. Principal Investigator.
  Funding Agency

  Irish Research Council for Science, Engineering and Technology
  Date From

  2010
  Date To

  2013
• Title

  HRB PhD Scholars programme in Immunology.
  Summary

  Coapplicant for funding: Awarded to Trinity College Dublin in partnership with the Institute of Immunology (NUI Maynooth) and the Division of infection and Immunity (Queens University Belfast). Partner. Budget allocated to Dr Ed Lavelle (303,360).
  Funding Agency

  HRB
  Date From

  2007
  Date To

  2011
• Title

  Development of novel Liquid/Emulsion Drug Delivery System (LEDDS ) formulations for oral vaccination (2007)
  Summary

  IP 2007 0451. Principal Investigator.
  Funding Agency

  Enterprise Ireland
  Date From

  2007
  Date To

  2009
• Title

  'The Identification of novel immunomodulatory factors from Neisseria meningitidis serogroup B'
  Summary

  : Use of high throughput protein expression and dendritic cell screening technologies to identify novel adjuvants. Principal Investigator.
  Funding Agency

  Meningitis Research Foundation/Health Research Board
  Date From

  2007
  Date To

  2010
• Title

  SFI Strategic Research Cluster Grant. (2008).
  Summary

  Co-applicant for funding: Cluster. 7.5m. Co-applicant, PI Prof Kingston Mills. Budget allocated to Dr Ed Lavelle €794,498.
  Funding Agency

  SFI Strategic Research Cluster Grant.
  Date From

  2008
  Date To

  2012
• Title

  Irish Society for Immunology Workshop on the Microbiota and Clinical Immunology.
  Summary

  .14/CW/B016.
  Funding Agency

  Science Foundation Ireland (SFI)
  Date From

  2014
  Date To

  2014
• Title

  SFI Research Centre, Advanced Materials and Bioengineering Research (AMBER) centre
  Summary

  Co-applicant for funding: Grant number SFI/12/RC/2278. Funded investigator. Projected budget to Ed Lavelle € 904,000k
  Funding Agency

  SFI
  Date From

  2013
  Date To

  2019
• Title

  Irish Society for Immunology meeting 2015.
  Summary
  Funding Agency

  Science Foundation Ireland (SFI)
  Date From

  1-6-2015
  Date To

  31-12-2015
• Title

  Sugar coating immunity for enhancement of biomaterials.
  Summary

  18/TIDA/6087.
  Funding Agency

  Science Foundation Ireland
  Date From

  1-1-2019
  Date To

  31-10-2020
• Title

  Development of novel oral vaccines using LEDDS technology.
  Summary

  (2010).IRCSET-Sigmoid 2010-01. 2010-2013. Time commitment 4%.
  Funding Agency

  Irish Research Council for Science, Engineering and Technology
  Date From

  2010
  Date To

  2013
• Title

  'Mucosal vaccines for poverty related diseases'
  Summary

  Co-applicant for funding: Project acronym: MUVAPRED. Title of grant: . Amount awarded was €350,000. 2003-2007. Summary: Development of mucosal vaccines for malaria, TB and HIV using novel mucosal adjuvants and delivery systems. Partner.
  Funding Agency

  EU
  Date From

  2003
  Date To

  2007
• Title

  Adjuvants targeting the NLRP3 inflammasome and STING for improved cancer immunotherapy.
  Summary
  Funding Agency

  Irish Research council
  Date From

  1-10-2019
  Date To

  30-9-2-23
• Title

  European Mucosal Immunology Group meeting 2012
  Summary

  12/CW/B2256. (EMIG2012).
  Funding Agency

  SFI
  Date From

  2012
• Title

  Targeted oral delivery of cyclosporine to inhibit pathological intestinal IL-17 responses.
  Summary

  Project ID: EPSPG/2017/302.
  Funding Agency

  Irish Research Council
  Date From

  1-1-2018
  Date To

  1-1-2022
• Title

  Can the ability of chitosan to promote innate immunity be harnessed to develop safe and potent adjuvants? (2008)
  Summary

  Proposal ID. 08/RFP/BMT1363. Principal Investigator.
  Funding Agency

  Science Foundation Ireland
  Date From

  2008
  Date To

  2011
• Title

  Optimisation of liquid emulsion drug delivery system (LEDDS based oral vaccines to promote protective immunity against mucosal pathogens.
  Summary

  (2010). Proposal ID, IP20090046. Principal investigator.
  Funding Agency

  Enterprise Ireland
  Date From

  2010
  Date To

  2012
• Title

  Advanced Immunization Technologies ADITEC
  Summary

  Co applicant: Affiliated member. Budget to Lavelle lab 47k.
  Funding Agency

  European Union
  Date From

  2012
  Date To

  2017
• Title

  Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of cancer
  Summary
  Funding Agency

  Trinity St. James's Cancer Institute
  Date From

  2018
  Date To

  2019
• Title

  Immunomodulatory properties of rhamnose
  Summary

  Trinity College Dublin College Award to Mimmi Lundahl. €39,000 (2015-2018)
  Funding Agency

  Trinity College Dublin
  Date From

  1-10-2015
  Date To

  1-10-2019
• Title

  Potential of oral cyclosporine to treat extra-intestinal diseases
  Summary
  Funding Agency

  Sublimity Therapeutics
  Date From

  1-5-2019
  Date To

  30-9-2020
• Title

  European Congress of Immunology
  Summary

  The Business Tourism Unit of the National Tourism Development Authority (Fáilte Ireland) has approved an offer of grant assistance in respect of the above conference.
  Funding Agency

  Failte Ireland
  Date From

  14-3-2018
  Date To

  31-12-2024
• Title

  Irish Society for Immunology meeting 2018.
  Summary

  Proposal ID: 18/CW/5605.
  Funding Agency

  Science Foundation Ireland (SFI)
  Date From

  1-6-2018
  Date To

  31-12-2018
• Title

  Modulation of innate and adaptive immunity by particulate adjuvants for improved parenteral and mucosal vaccination.
  Summary

  12/1A/1421.
  Funding Agency

  SFI
  Date From

  2013
  Date To

  2019
• Title

  Mucosal vaccines for TB, HIV and malaria
  Summary
  Funding Agency

  EU
  Date From

  2004
  Date To

  2009
• Title

  RAdiosensitising Yb-1 Nano-antiBOdy (RAYNBO): a proof of concept study
  Summary
  Funding Agency

  Trinity St. James's Cancer Institute
  Date From

  2018
  Date To

  2019
• Title

  Targeted mucosal vaccines for HIV-Postgraduate award. 2010
  Summary

  Principal Investigator.
  Funding Agency

  Irish Research Council for Science, Engineering and Technology
  Date From

  2010
  Date To

  2013
• Title

  A determination of the efficacy of LEDDS as an oral vaccine delivery system.
  Summary

  Summary: Investigation of novel delivery systems for oral vaccines. Principal Investigator.
  Funding Agency

  Sigmoid Biotechnologies Limited (2006).
  Date From

  2006
  Date To

  2007
• Title

  Tailored design of nanoparticulate adjuvants to enhance vaccine induced cellular immunity
  Summary
  Funding Agency

  Science Foundation Ireland
  Date From

  1-10-2020
  Date To

  30-9-2025
• Title

  Development of novel immunostimulators to boost the immune system in cattle.
  Summary

  Adacemic Principal Investigator
  Funding Agency

  TEAGASC
  Date From

  2012
• Title

  Development of potent mucosal vaccines by combining an effective targeting agent with immunostimulatory particulate adjuvants.
  Summary

  Proposal ID, IP20090022. Principal investigator.
  Funding Agency

  Enterprise Ireland
  Date From

  2010
  Date To

  2012
• Title

  Development of patented targeting technologies to produce oral vaccines.
  Summary

  IP 2006 0372. Summary: Investigation of novel cell targeting technologies to enhance mucosal vaccines. Principal Investigator.
  Funding Agency

  Enterprise Ireland
  Date From

  2006
  Date To

  2007
• Title

  HELICOVAXOR (2013), Development of novel mucosal vaccines against Helicobacter pylori infection.
  Summary

  Amount awarded is €1.3. Budget allocated to Dr Ed Lavelle €250,900. My role is as an RTD performer working on mucosal vaccination and determination of antigen specific cellular and humoral immunity.
  Date From

  2013
  Date To

  2015
• Title

  Determination of the potential of novel LEDDS formulations as oral vaccine delivery systems
  Summary

  IP 2006 0422 Principal Investigator
  Funding Agency

  Enterprise Ireland
  Date From

  March 07
  Date To

  May 07
• Title

  Development of novel Liquid/Emulsion Drug Delivery System (LEDDS ) formulations for oral vaccination IP 2007 0451
  Summary

  Development of novel delivery systems for oral vaccination
  Funding Agency

  Enterprise Ireland
  Date From

  2007
  Date To

  2009
• Title

  Investigating the role of Mal/TIRAP and the Mal- S180L SNP as determinants of susceptibility to pneumococcal disease and antipneumoco ccal vaccine efficacy
  Summary
  Funding Agency

  European Society for Clinical Microbiolo gy and Infectious Diseases (ESCMID)
  Date From

  1-5-2018
  Date To

  31-10-2019

Biochemistry and cell biology, Immunology, Nanotechnology,

• Made an ambassador of the Dublin Convention Centre 2018
• Elected a Member of the Royal Irish Academy (MRIA) 2021
• Elected President of the European Congress of Immunology 2024 (ECI2024) 2021
• Elected President of the Irish Society for Immunology 2012
• Fellow of Trinity College Dublin (FTCD) 2012

• Committee member of the Vaccine committee for the International Union of Immunological Societies (IUIS). 2022
• European Federation of Immunology Societies 2022
• Society for Mucosal Immunology 2022
• The American Association of Immunologists 2022
• Irish Society for Immunology (President 2008-2020) 2022
• International Society of Vaccines 2022
• European Adjuvant Advisory Group 2008

• Member of the Editorial Board of Biochemical Pharmacology and Frontiers in Immunology
• Member of the Scientific Advisory Panel for 13 international conferences since 2006.
• Main organiser of 9 Immunology meetings including the Irish Society for Immunology meetings (2013-2020; average attendance 160-200 participants) and the European Mucosal Immunology Group (EMIG) 2012 meeting (300 participants), held in Dublin.
• Member of the advisory board for the EU funded ITN, PHA-ST-TRAIN-VAC between the University of Strathclyde and GSK Vaccines (2017-2019).
• Member of the Scientific Advisory Panel for 13 international conferences since 2006.
• Member of the Editorial Board of Biochemical Pharmacology and Frontiers in Immunology
• Main organiser of 9 Immunology meetings including the Irish Society for Immunology meetings (2013-2020; average attendance 160-200 participants) and the European Mucosal Immunology Group (EMIG) 2012 meeting (300 participants), held in Dublin.
• Member of the advisory board for the EU funded ITN, PHA-ST-TRAIN-VAC between the University of Strathclyde and GSK Vaccines (2017-2019).
• Chair of the Steering committee for the Centre for Global Vaccine Research, University of Liverpool, U.K. (2017-2020).
• National representative and member of the core group of the COST Action ENOVA (European Network of Vaccine adjuvants) 2018-2022.
• National representative and member of the core group of the COST Action ENOVA (European Network of Vaccine adjuvants) 2018-2022.
• Chair of the Steering committee for the Centre for Global Vaccine Research, University of Liverpool, U.K. (2017-2020).
• Won the bid to host the 2024 European Congress of Immunology in Dublin in 2024. I will lead the committee in planning for this meeting for the coming 5 years.
• Won the bid to host the 2024 European Congress of Immunology in Dublin in 2024. I will lead the committee in planning for this meeting for the coming 5 years.